NCT06845033Active, not recruiting
Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
The naturally occurring peptide hormone liver-expressed antimicrobial peptide 2 (LEAP2) in an antagonist/inverse agonist towards the ghrelin receptor. Ghrelin administration has previously been shown to increase food cue reactivity in brain regions related to appetite and reward using functional MRI scans. The aim of this clinical study is to investigate the effects of LEAP2 infusion on food cue reactivity in brain regions related to appetite and reward. Since LEAP2 is an antagonist/inverse agonist towards the ghrelin receptor we hypothesize, that LEAP2 infusion will decrease food cue reactivity in the above-mentioned regions compared to placebo infusion. Participants with obesity (BMI 30-50 kg/m2) will be included and complete two experimental days with either LEAP2 or placebo infusion in a randomized crossover manner. On experimental days, participants will undergo a MRI scan with functional and anatomical modalities. The study will attribute to gain a deeper understanding of the ghrelin system and its interaction with appetite regulation.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- First submitted
- 7 Feb 2025
- Start date
- 1 May 2025
- Primary completion date
- 3 Mar 2026
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Diseases
- Obesity
- NCT number
- NCT06845033
What you commit to
- Study type: Interventional
- Planned participants: 28
- From 1 May 2025 to the primary completion date, 3 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any ongoing medication that the investigator evaluates would interfere with trial participation.
Other illness
- Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) \>2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s)
- Any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses
Lab values
- Anaemia (haemoglobin below normal range)
- Nephropathy (serum creatinine above normal range and/or albuminuria)
- Glycated haemoglobin (HbA1c) ≥48 mmol/mol and/or type 2 diabetes requiring medical treatment
Other
- Regular tobacco smoking or use of other nicotine-containing products
- Claustrophobia
Who the study is looking for
- Age between 18 and 60 years at the time of inclusion
- Body mass index 30-50 kg/m2
- Men
- Informed consent
Age in the registry: 18 years to 60 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Clinical Metabolic Research Coordinator of this site? Confirm its status | Hellerup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.